A total of 60 patients will be selected based on the set inclusion and exclusion criteria. A written informed consent will be obtained from each patient before the start of the study. Case history related to TMD will be collected by means of Diagnostic Criteria questionnaire and subsequent clinical examination will be performed. Pain will be assessed by means of visual analog scale. The radiographic examination of the TMJ will be done after the clinical examination to rule out fractures, cysts etc.

Patients will be allocated into 2 groups, Group A[AQUEOUS TITANIUM PATCH 540 ml/l] and Group B[DICLOFENAC PATCH 100 mg] of 30 each by simple random method using a computer generated sequence. Their allocation is concealed by providing them with sequentially numbered opaque envelopes with patient number on outside. The envelope is placed at the custody of the guide and will be opened only during intervention. To eliminate bias, both outcome assessor and patient will be blinded. Code breaking will be performed after statistical analysis. A patch test will be done by the application of test patch on the forearm and observing the skin reaction for 1 hour for detection of allergy. If the patient experiences any signs of allergy, he will be excluded from the study. If no allergic reactions develop the patient will be provided with respective transdermal patches for application onto the painful area for 12 hours a day over 2 weeks duration. No adjuvant therapy is given to the patient during the study period. After 2 weeks the patch application is withdrawn. The patient will be reviewed

and reassessed for outcome measures, pain by visual analog scale during rest and during jaw movements and maximum range of mouth opening, with and without pain periodically on 3rd,7th,15th and 21st days.If patient develops any adverse effects during the study at any point of time, he will be excluded and appropriate therapy will be given.